Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$44.21
$1.55(3.95%)
At close: 4:00 PM EDT
$44.21
$1.55(3.95%)
Day’s Range― - ―
52-Week Range$14.68 - $48.51
Previous Close$40.84
Volume1.03M
Average Volume (3M)1.57M
Market Cap
$4.12B
Enterprise Value$3.92B
Total Cash (Recent Filing)$460.71M
Total Debt (Recent Filing)$3.59M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 05, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding108,604,126
10 Day Avg. Volume1,400,965
30 Day Avg. Volume1,565,171
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.64K
Enterprise Value/Ebitda-20.10
Forecast
1Y Price Target
$51.11Price Target Upside15.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageExtremely low leverage limits refinancing and interest-rate exposure while preserving financial flexibility for clinical development. The sizable equity base gives Edgewise a stronger solvency position than many development-stage biotechs, although continued losses remain a constraint.
Major Upfront Asset-sale FundingThe substantial upfront payment materially extends funding capacity and can support the company’s development programs without relying as heavily on near-term borrowing or equity issuance. It also sharpens strategic focus on Edgewise’s cardiovascular pipeline and reduces immediate financing pressure.
Cardiovascular Pipeline AdvancementStarting a Phase 2 study moves EDG-15400 into a more advanced clinical stage and establishes a concrete cardiovascular development path. Progress in HFpEF broadens the company’s pipeline beyond its original muscle-disease focus and creates another potential source of long-term value.
Bears Say
No Commercial RevenueWith no reported revenue, Edgewise remains dependent on financing, partnerships, or asset-related proceeds to fund operations rather than internally generated sales. This keeps the business model structurally pre-commercial and makes future financial performance highly dependent on clinical and regulatory execution.
Widening Net LossesThe widening loss trend indicates that operating and clinical-development spending is increasing faster than any offsetting revenue generation. Persistent losses can erode the equity base over time and raise the amount of capital required before the pipeline can support a commercially sustainable business.
Heavy Negative Cash FlowLarge recurring cash outflows show that clinical operations are consuming substantial resources and that the company is not yet self-funding. Even with improved liquidity from the asset sale, sustained burn may reduce financial flexibility and increase dependence on successful pipeline progression.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $14.68 and its highest was $48.51 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $4.12B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.468 by -$0.062.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.53.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 108,604,126 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.468. Following the earnings report the stock price went down -1.267%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.11 (15.61% Upside)
$51.11 (15.61% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.28%
12-Months-Change
Fundamentals
Return on Equity
-39.01%
Trailing 12-Months
Asset Growth
-21.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$51.11
▲(15.61% Upside)
Technical Analysis
Sarepta Therapeutics
―
PTC Therapeutics
―
Solid Biosciences
―
Scholar Rock Holding
―
Dyne Therapeutics
―
Ownership Overview
0.59% Insiders
13.77% Mutual Funds
0.68% Other Institutional Investors
74.97% Public Companies and
Individual Investors